1. The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis. (4th May 2019) Authors: Freedman, M. S.; Duquette, P.; Grand'Maison, F.; Lee, L.; Vorobeychik, G.; Lara, N.; Khurana, V.; Nakhaipour, H. R.; Schecter, R.; Haddad, P. Journal: Current medical research and opinion Issue: Volume 35:Number 5(2019) Page Start: 767 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗